Hepatology Research

Papers
(The TQCC of Hepatology Research is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach99
Liver injury is associated with severe coronavirus disease 2019 (COVID‐19) infection: A systematic review and meta‐analysis of retrospective studies94
Evidence‐based clinical practice guidelines for liver cirrhosis 202084
Longitudinal changes of liver function and hepatitis B reactivation in COVID‐19 patients with pre‐existing chronic hepatitis B virus infection59
Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update59
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update57
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 202055
MAFLD: Renovation of clinical practice and disease awareness of fatty liver53
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis45
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)37
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong37
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan35
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study34
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)34
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma32
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice31
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)30
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study30
Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison betw30
Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non‐invasive tests for the diagnosis of advanced liver fibrosis in patients with non‐alcoholic fatty li29
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria29
Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction27
Hepatocellular carcinoma after Fontan surgery: A systematic review26
Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people26
Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab26
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy26
Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan26
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis26
Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classification25
Association of coagulopathy with liver dysfunction in patients with COVID‐1925
Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors25
Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis25
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma24
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis23
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases23
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matche22
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis22
Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study21
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease21
Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC20
JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis20
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX920
Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease20
Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen20
Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy19
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multic19
Characteristics of hepatocellular carcinoma arising from Fontan‐associated liver disease19
LINC02499, a novel liver‐specific long non‐coding RNA with potential diagnostic and prognostic value, inhibits hepatocellular carcinoma cell proliferation, migration, and invasion19
Artificial liver treatment improves survival in patients with hepatitis B virus‐related acute‐on‐chronic liver failure: A case‐control matched analysis18
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria18
Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization18
High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C18
Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection17
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis17
Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works17
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease16
Serum matrix metalloproteinase‐7 in biliary atresia: A Japanese multicenter study16
Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma16
Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma16
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma16
Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma15
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma15
aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C15
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression15
Liver disease in pregnancy14
Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis14
Association between the albumin–bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data‐mining analysis14
Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment13
Novel strategies for the early diagnosis of hepatitis B virus reactivation12
A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases12
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis12
Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review12
Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoemboliz12
Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study12
The stratification of cirrhosis12
Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine‐1‐phosphate and ceramide in human hepatocellular carcinoma12
Impact of viral eradication by direct‐acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus‐related compensated cirrhosis patie12
Non‐invasive fibrosis markers are associated with mortality risk in both general populations and non‐alcoholic fatty liver disease patients12
Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function12
Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology12
Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐1911
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era11
Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study11
Omics‐derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases11
Controlled attenuation parameter by vibration‐controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonanc10
Effects of a low‐intensity resistance exercise program on serum miR‐630, miR‐5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study10
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma10
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)10
Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment10
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study10
Metabolomic/lipidomic‐based analysis of plasma to diagnose hepatocellular ballooning in patients with non‐alcoholic fatty liver disease: A multicenter study10
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease10
Management of portal hypertension based on portal hemodynamics10
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade9
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma9
Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population9
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia9
Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta‐analysis of propensity score studies9
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials9
Assessing liver stiffness with conventional cut‐off values overestimates liver fibrosis staging in patients who received the Fontan procedure9
Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis9
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease9
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis9
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma9
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension8
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease8
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan8
Treatment outcomes of stereotactic body radiation therapy using a real‐time tumor‐tracking radiotherapy system for hepatocellular carcinomas8
Proposal of Stroop test cut‐off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study8
Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma8
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay8
The efficacy of rituximab treatment for antibody‐mediated rejection in liver transplantation: A retrospective Japanese nationwide study8
NBAS disease: 14 new patients, a recurrent mutation, and genotype–phenotype correlation among 24 Chinese patients8
Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database8
Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma7
Comparison of embolic effect between water‐in‐oil emulsion and microspheres in transarterial embolization for rat hepatocellular carcinoma model7
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma7
Serum Gas6 and Axl as non‐invasive biomarkers of advanced histological stage in primary biliary cholangitis7
The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis7
Multicenter study on the consciousness‐regaining effect of a newly developed artificial liver support system in acute liver failure: An on‐line continuous hemodiafiltration system7
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis7
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained 7
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients7
Hepatocellular adenoma, approximately half and predominantly inflammatory subtype, in 38 Japanese patients with several differences in age, gender, and clinical background factors from Western populat7
Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching7
Single nucleus transcriptomics data integration recapitulates the major cell types in human liver7
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 20167
Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease6
Association between dietary patterns and prognosis of hepatocellular carcinoma in the Guangdong liver cancer cohort study6
Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection6
Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism6
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis6
Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study6
Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver‐related complications6
Significant improvement in portal‐systemic liver failure symptoms and successful management of portal‐splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy6
Donor‐dominant one‐way matching of human leukocyte antigen‐A/B/DR alleles predicts graft‐versus‐host disease following living donor liver transplantation6
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis6
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample6
Prognosis of patients with liver cirrhosis: A multi‐center retrospective observational study6
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population6
Outcome of patients with acute liver failure awaiting liver transplantation in Japan6
Angiopoietin‐like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells6
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population6
Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus6
Hepatic stellate cell as a Mac‐2‐binding protein‐producing cell in patients with liver fibrosis6
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study6
Chemical conversion of aged hepatocytes into bipotent liver progenitor cells6
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma6
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study6
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma6
0.054327964782715